DETROIT, March 28, 2011 /PRNewswire-USNewswire/ — Detroit
Medical Center (DMC) Cardiovascular Institute (CVI) announced its
first implant of the AngelMed Guardian cardiac monitor and alert
system. The system is designed to reduce the time it takes patients
to get to the emergency room during an impending heart attack.
Randy Lieberman, M.D., Medical Director, Electrophysiology
Services, DMC CVI, performed the first implant in Southeast
Michigan, and is among the very first physicians across the United
States to implant the experimental device.
The AngelMed Guardian system is designed to track significant
changes in the heart’s electrical signal and then alert patients to
seek medical attention. The objective of the ALERTS Pivotal
Study is to provide an assessment of the safety and effectiveness
of the AngelMed Guardian System.
“This study provides an excellent opportunity for some of our
patients who are at high-risk of having another heart attack. The
device is designed to measure changes in the electrical signal of
the heart and alert the patient at the earliest onset of a heart
attack so that they can get treatment as soon as possible,” said
Dr. Lieberman.
According to the American Heart Association, one of every five
deaths in the United States is attributable to coronary heart
disease. Further, 50 percent of heart-attack fatalities occur
within one hour of symptom onset and occur before the patient even
reaches the hospital.
The AngelMed Guardian System is comprised of an internal
implantable device about the size of a standard pacemaker with a
lead into the heart, an external telemetry device, and a programmer
that aids physicians in evaluating heart signals.
DMC Cardiovascular Institute is among the first medical
facilities to participate in the AngelMed Guardian system trial. To
participate in the ALERTS study, patients must meet various
inclusion criteria. For more information on the AngelMed Guardian
syste
‘/>”/>
